BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Update

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 137,800 shares, an increase of 17.1% from the November 30th total of 117,700 shares. Based on an average daily trading volume, of 120,600 shares, the short-interest ratio is currently 1.1 days.

BioStem Technologies Stock Performance

BSEM stock traded down $0.17 during midday trading on Friday, reaching $12.65. 24,767 shares of the company traded hands, compared to its average volume of 38,335. The firm has a market capitalization of $210.28 million, a price-to-earnings ratio of 18.60 and a beta of -0.62. BioStem Technologies has a 52-week low of $4.41 and a 52-week high of $28.26. The business has a 50 day moving average of $15.84 and a 200-day moving average of $12.06.

BioStem Technologies (OTCMKTS:BSEM) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.01. The company had revenue of $82.56 million for the quarter, compared to analysts’ expectations of $78.22 million. Research analysts anticipate that BioStem Technologies will post 1.41 earnings per share for the current year.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.